Fracture Risk Up With Insulin Compared With Metformin in T2DM
Risk for major osteoporotic fractures up for insulin versus metformin for those with HbA1c <7 percent, BMI <25 kg/m2
Risk for major osteoporotic fractures up for insulin versus metformin for those with HbA1c <7 percent, BMI <25 kg/m2
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.
Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
FDA received licensing applications sooner and had shorter review times, compared to the European Medicines Agency
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
A meta-analysis revealed that RAAS inhibitor monotherapy in patients with primary FSGS is significantly associated with a 32% reduction in proteinuria.
The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.
Compared with placebo, normalization of C-reactive protein and oxygen saturation faster, with improvements seen on day 3 of treatment
No medication is currently approved to treat vascular calcification in this population.